Lloyd Diamond, Chief Executive Officer of Pixium Vision
.
“The Prima System has demonstrated its potential to make a significant improvement to the quality of life of patients with dry AMD and this award recognizes its capacity to improve vision. I would like to thank the entire Pixium Vision team and our collaborators for their dedication in developing the Prima System and progressing it through clinical trials and towards patients in desperate need of
treatment.”
The Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic dry age-related macular degeneration (AMD), is being studied in the pivotal PRIMAvera trial. The study was initiated in Q4 2020 and aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.